TrialMedical oncology (Northwood, London, England)2015

Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study.

Xiaohui Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.